Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Proof of Principle Program - Phase I

McGill University

$160,000.00

Buccal Lamin A as a Novel Biomarker for Frailty

EF 2012-13

Résumé
Given the aging patient population and rising healthcare costs, physicians have become acutely aware of the need to prevent patients from receiving costly but un-useful procedures. Age alone is a flawed way to predict which patients will suffer poor outcomes when exposed to invasive procedures. Frailty is a geriatric condition that reflects biological age ("true age") and presents a better way to characterize elderly patients and their risks. Several tools exist to measure frailty (questionnaires, physical tests) but their adoption has been limited because they are felt to be subjective and time-consuming. A biomarker for frailty would be highly desirable but has yet to be developed. We discovered a novel association between frailty and lamin A - the nuclear protein commonly known for its role in the accelerated aging syndrome Progeria. We found that lamin A levels declined with age, and furthermore, declined in parallel with frailty status. Since we and others noted that lamin A was not expressed in blood, we derived a test to measure lamin A levels in buccal cells harvested from a simple cheek swab. Using a quantitative flow cytometry platform, we quantified lamin A levels in an accurate and reproducible manner. This grant involves developing our own monoclonal antibodies against lamin A and its precursors and further optimizing and validating our diagnostic test to meet the rigorous standards needed for commercialization. The application of our test will be evaluated in clinical studies where we will use our lamin A test as a biomarker for frailty to predict which patients are likely to suffer poor outcomes after cardiac surgery. This is central to the contemporary practice of personalized medicine, where we can now consider offering less invasive therapies to our vulnerable patients. Beyond exploring lamin A as a predictor of outcomes, we will measure lamin A in healthy volunteers of various ages to determine age-adjusted normative values.
Programme
Proof of Principle Program - Phase I
Bénéficiaire
Emplacement
Quebec, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
268607
Name
Afilalo Jonathan
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Aging
Theme2
Biomedical
Prcname2
Proof of Principle
Projecttitle
Buccal Lamin A as a Novel Biomarker for Frailty
Programtype2
Operating Grants
Orgnameinp2
McGill University
Cihramount2
$160,000
Cihrequipment2
$0
Programname2
Proof of Principle Program - Phase I
Keyworddelim
Aging; Biomarker; Cardiac Surgery; Frailty; Lamin
Abstract
Given the aging patient population and rising healthcare costs, physicians have become acutely aware of the need to prevent patients from receiving costly but un-useful procedures. Age alone is a flawed way to predict which patients will suffer poor outcomes when exposed to invasive procedures. Frailty is a geriatric condition that reflects biological age ("true age") and presents a better way to characterize elderly patients and their risks. Several tools exist to measure frailty (questionnaires, physical tests) but their adoption has been limited because they are felt to be subjective and time-consuming. A biomarker for frailty would be highly desirable but has yet to be developed. We discovered a novel association between frailty and lamin A - the nuclear protein commonly known for its role in the accelerated aging syndrome Progeria. We found that lamin A levels declined with age, and furthermore, declined in parallel with frailty status. Since we and others noted that lamin A was not expressed in blood, we derived a test to measure lamin A levels in buccal cells harvested from a simple cheek swab. Using a quantitative flow cytometry platform, we quantified lamin A levels in an accurate and reproducible manner. This grant involves developing our own monoclonal antibodies against lamin A and its precursors and further optimizing and validating our diagnostic test to meet the rigorous standards needed for commercialization. The application of our test will be evaluated in clinical studies where we will use our lamin A test as a biomarker for frailty to predict which patients are likely to suffer poor outcomes after cardiac surgery. This is central to the contemporary practice of personalized medicine, where we can now consider offering less invasive therapies to our vulnerable patients. Beyond exploring lamin A as a predictor of outcomes, we will measure lamin A in healthy volunteers of various ages to determine age-adjusted normative values.
Competitiondate
201209
Approvedterm2
1 yr 0 mth
Pinamesdelim
Afilalo, Jonathan
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $160,000~ $0~